NovaMedica gets Russian rights for three gastrointestinal products from Omega Pharma

27 January 2015

PRB Production and Manufacturing

NovaMedica and Belgian pharmaceutical firm Omega Pharma have signed a partnership agreement to promote, distribute and sell a line of OTC gastrointestinal products under Benegast brand in Russia.

NovaMedica plans to begin marketing Benegast products in January 2015. Major products in the portfolio include: Benegast Reduflux, Benegast Redugas and Benegast Regulamine.

Reduflux contains the proprietary compound Phycodol that provides fast and sustainable relief from heartburn and indigestion.

The company said that Redugas reduces bloating and restores healthy gut flora, through its key ingredient Lycosyl, an effective combination of Simethicone and prebiotics (Inulin).

Regulamine contains Chiasyll, a combination of Psyllium Husk with Chia Seed, two types of soluble and insoluble fibers to restore and maintain regularity.

NovaMedica executive director Sergey Beloborodov said: "Partnering with Omega Pharma is in line with NovaMedica's strategy and our focus on delivering innovative treatments for gastrointestinal (GI) patients.

"The Benegast portfolio has strong synergies with NovaMedica's current line of GI pharmaceutical products.

"Benegast products have been marketed successfully in Europe and are ready for fast-track launch in Russia. This is the first umbrella brand solution to address most common symptoms in gastroenterology, and we are confident of its commercial success."

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more